- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00286624
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (NITA)
A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I/II study designed to assess the safety and efficacy of sequential islet allotransplantation for the reestablishment of stable glycemic control in type 1 diabetic recipients. A total of 6 patients with type 1 diabetes have received up to three transplants of islets from different donor pancreases.
Potential candidates for islet allotransplantation included patients age 18 and older with type 1 diabetes. Induction immunotherapy for the first transplant consisted of anti-thymocyte globulin; basiliximab was used for any subsequent transplants. Peritransplant anti-inflammatory treatment with etanercept was given for each islet transplant. Maintenance immunosuppression is with cyclosporine and RAD. It is felt that those patients in whom metabolic lability/instability, reduced awareness of hypoglycemia, poor glycemic control, and progressive secondary complications persist despite continued and intensive efforts made in close cooperation with their diabetes care team are particularly likely to have a favorable benefit/risk ratio.
Adverse events, irrespective of their presumed relationship to the transplantation of allogeneic islets and/or protocol-regulated treatment products (concomitant therapy), are being monitored and recorded throughout the first year after the final islet transplant.
The proportion of single and sequential donor islet allograft recipients with full (insulin independence and HbA1c <7%) and partial (insulin dependence, basal or arginine-stimulated C-peptide levels of greater or equal to 0.5 ng/mL and HbA1c <7%) islet graft function at one year after the final islet transplant will be assessed. The impact of islet transplantation on quality of life will also be assessed.
The predictive value for posttransplant insulin independence of factors such as insulin resistance before and at intervals after pancreatectomy, cellular composition of the transplant, number of beta cells transplanted; and viability and insulin secretory response of isolated islets are being assessed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary islet allotransplant
- Patients with type 1 diabetes mellitus under intensive insulin management
- Age 18 or older
- Ability to give written informed consent
Exclusion Criteria:
- Age less than 18 years.
- BMI >26 kg/m2.
- Insulin requirement of > 50 IU per day.
- Positive C-peptide response to intravenous arginine stimulation.
- Untreated proliferative retinopathy.
- Creatinine clearance < 60 ml/min/1.73 m2 for females and 70 ml/min/1.73 m2 for males.
- Serum creatinine >1.3 mg/dl for females, >1.5 mg/dl for males.
- Previous pancreas or islet transplant.
- Presence of history of panel-reactive anti-HLA antibodies >10%.
- Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures.
- Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB).
- Negative screen for Epstein-Barr Virus (EBV).
- Invasive aspergillus infection within year prior to study entry.
- History of malignancy.
- Active alcohol or substance abuse
- History of non-adherence to prescribed regimens.
- Psychiatric disorder making the subject not a suitable candidate for transplantation.
- Inability to provide informed consent.
- Baseline Hgb < 11.7 g/dl in females, or < 13 g/dl in males; lymphopenia (<1,000/microL), or leukopenia (<3,000 total leukocytes/microL), or an absolute CD4+ count <500/microL., or platelets <150,000/microL
- History of coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or patient with INR >1.5.
- Severe co-existing cardiac disease.
- Baseline liver function tests outside of normal range or history of significant liver disease.
- Active peptic ulcer disease.
- Severe unremitting diarrhea or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications.
- Presence of severe allergy requiring acute or chronic treatment, or hypersensitivity to drugs similar to RAD (e.g., macrolides).
- Known hypersensitivity to rabbit proteins.
- Hyperlipidemia (fasting LDL cholesterol > 130 mg/dl, treated or untreated; and/or fasting triglycerides > 200 mg/dl).
- Addison's disease.
- Under treatment requiring chronic use of systemic steroids.
- Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
|
Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans.
First infusion to contain at least 5,000 islet equivalents/kg body weight.
Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
Other Names:
Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID.
The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
Other Names:
A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2.
The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
Other Names:
Cyclosporine started on day +1 relative to the first islet transplant.
Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• The incidence, timing, and severity of adverse events during one year after the first and any subsequent islet transplants.
Time Frame: 1 year
|
1 year
|
• Incidence and severity of hypoglycemia during the first year after the first and any subsequent islet transplants.
Time Frame: 1 yr
|
1 yr
|
• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• The proportion of subjects who achieve insulin independence in the first year after single-donor or sequential transplantation.
Time Frame: 1 year
|
1 year
|
• The proportion of islet allograft recipients with full and partial islet graft function at one year after the most recent islet transplant.
Time Frame: 1 year
|
1 year
|
• Glycemic control and insulin secretory responses during the first year after the first and any subsequent transplants.
Time Frame: 1 year
|
1 year
|
• The effect of donor age, pretransplant islet insulin secretory response in vitro, number of transplanted islet equivalents (IEQ), number of transplanted beta cells, pretransplant recipient insulin requirements and action, recipient body mass index (BM
Time Frame: Day of transplant
|
Day of transplant
|
• The impact of islet transplantation on the quality of life of transplant recipients.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Everolimus
- Antilymphocyte Serum
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- 0207M29841
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia
-
University of UlmRecruitingHypoglycemia, ReactiveGermany
-
University of ArizonaNot yet recruiting
-
Milton S. Hershey Medical CenterDexCom, Inc.; Children's Miracle NetworkRecruiting
-
Zealand University HospitalUnknownHypoglycemia, ReactiveDenmark
-
MBX BiosciencesProSciento, Inc.RecruitingPostbariatric HypoglycemiaUnited States
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
University of NebraskaCompletedNeonatal HypoglycemiaUnited States
-
Vogenx, Inc.CompletedPostbariatric HypoglycemiaUnited States
-
Stanford UniversityCompletedNeonatal HypoglycemiaUnited States
-
Diva De LeonLester and Liesel Baker FoundationCompletedPostprandial HypoglycemiaUnited States
Clinical Trials on Allogeneic Islets of Langerhans
-
University of MinnesotaAvailableHypoglycemia | Type 1 Diabetes Mellitus | End-stage Renal Disease | Labile DiabetesUnited States
-
CellTrans Inc.Approved for marketingType 1 Diabetes MellitusUnited States
-
University of MinnesotaJuvenile Diabetes Research Foundation; National Institutes of Health (NIH)CompletedHypoglycemia | Type 1 Diabetes MellitusUnited States
-
University of NebraskaTerminatedDiabetes Mellitus, Type 1 | Islets of Langerhans TransplantationUnited States
-
University of MinnesotaJuvenile Diabetes Research FoundationCompletedHypoglycemia | Type 1 DiabetesUnited States
-
University of MinnesotaJuvenile Diabetes Research Foundation; Roche Pharma AGCompletedHypoglycemia | Type 1 DiabetesUnited States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Wyeth...UnknownDiabetes Mellitus, Type 1United States
-
University of MinnesotaJuvenile Diabetes Research FoundationTerminatedHypoglycemia | Type 1 Diabetes MellitusUnited States
-
Emory UniversityJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1United States
-
CellTrans Inc.Active, not recruitingType 1 Diabetes MellitusUnited States